This company has shut down. VectivBio is no longer operating — its last tracked round was a Post-IPO Equity in 2022.
Explore the Startup GraveyardVectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
VectivBio has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2022.
VectivBio's investors include Bpifrance, Vivo Capital, TCG Crossover, OrbiMed, Forbion Capital Partners.
VectivBio is headquartered in Basel, Switzerland.
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
VectivBio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VectivBio — Funding & Investors." VCBacked, October 13, 2022, https://www.vcbacked.co/company/vectivbio. Accessed October 1, 2026.
VCBacked. (2022). VectivBio — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/vectivbio
{{cite web |title=VectivBio — Funding & Investors |url=https://www.vcbacked.co/company/vectivbio |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated